• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ARTV

    Artiva Biotherapeutics Inc.

    Subscribe to $ARTV
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IPO Year: 2024

    Exchange: NASDAQ

    Recent Analyst Ratings for Artiva Biotherapeutics Inc.

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    See more ratings

    Artiva Biotherapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Artiva Biotherapeutics with a new price target

      H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

      6/11/25 7:52:47 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

      12/30/24 7:13:58 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

      Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

      8/13/24 7:24:03 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Artiva Biotherapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Artiva Biotherapeutics with a rating of Overweight and set a new price target of $23.00

      8/13/24 7:23:42 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Artiva Biotherapeutics

      TD Cowen initiated coverage of Artiva Biotherapeutics with a rating of Buy

      8/13/24 7:23:42 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on Artiva Biotherapeutics with a new price target

      Wedbush initiated coverage of Artiva Biotherapeutics with a rating of Outperform and set a new price target of $18.00

      8/13/24 7:22:56 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on Artiva Biotherapeutics with a new price target

      Needham initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $23.00

      8/13/24 7:22:56 AM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Artiva Biotherapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Banerjee Subhashis was granted 50,000 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:07:02 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Banerjee Subhashis

      3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      4/25/25 5:03:53 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Aslan Fred was granted 200,000 shares, increasing direct ownership by 92% to 416,665 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      3/7/25 4:35:00 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Tech Operations Officer Horan Christopher was granted 60,000 shares, increasing direct ownership by 240% to 85,000 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      2/28/25 5:15:11 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Graef Thorsten was granted 60,000 shares, increasing direct ownership by 300% to 80,000 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      2/28/25 5:15:13 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, Research and Development Raymon Heather was granted 33,350 shares, increasing direct ownership by 334% to 43,350 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      2/28/25 5:15:16 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Krishnamohan Neha was granted 60,000 shares, increasing direct ownership by 120% to 110,000 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      2/28/25 5:15:08 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COO, CLO, Secy, Compliance Off Bush Jennifer was granted 86,650 shares, increasing direct ownership by 119% to 159,449 units (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      2/28/25 5:15:05 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Baker Daniel G.

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      1/29/25 4:33:38 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Baker Daniel G.

      3 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      1/29/25 4:32:16 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Artiva Biotherapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:27:11 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner 5am Partners Vi, Llc converted options into 1,058,284 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $9,999,996 worth of shares (833,333 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/24/24 4:15:09 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Venbio Global Strategic Fund Iii, L.P. bought $4,999,992 worth of shares (416,666 units at $12.00), converted options into 1,058,284 shares and acquired 461,687 shares (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/22/24 8:26:49 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Gc Corp. converted options into 1,352,252 shares, acquired $5,614,417 worth of shares (550,433 units at $10.20) and bought $24,999,984 worth of shares (2,083,332 units at $12.00) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/22/24 8:25:40 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Huh Yong-Jun bought $24,999,984 worth of shares (2,083,332 units at $12.00), converted options into 1,352,252 shares and acquired $5,614,417 worth of shares (550,433 units at $10.20) (SEC Form 4)

      4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

      7/22/24 8:22:03 PM ET
      $ARTV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care